Selected Grants
TBCRC053-N Protocol Title: "P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer (Triple Negative Cohort Only)"
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2022 - 2027TBCRC053-M-59105
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2027P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2024 - 2026" HR+ P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer (HR+ Cohort)"
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2024 - 2025P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Breast Cancer Research Foundation · 2023 - 2024External Relationships
- Elsevier Inc. Textbook Royalties
- Groombridge, Wu, Baughman & Stone LLP
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.